The New England journal of medicine, 2020-10, Vol.383 (16), p.1511-1521
2020
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis
- Ist Teil von
- The New England journal of medicine, 2020-10, Vol.383 (16), p.1511-1521
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2020
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- In a 24-week trial involving patients with rheumatoid arthritis that was refractory to biologic agents, the JAK1 inhibitor upadacitinib was superior to the T-cell costimulation modulator abatacept in reducing disease activity as assessed by a composite measure of joint changes and C-reactive protein level.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2008250Titel-ID: cdi_proquest_journals_2451155994
- Format
- –
- Schlagworte
- Abatacept - adverse effects, Abatacept - therapeutic use, Administration, Oral, Antirheumatic Agents - adverse effects, Antirheumatic Agents - therapeutic use, Arthritis, Rheumatoid - blood, Arthritis, Rheumatoid - drug therapy, C-reactive protein, C-Reactive Protein - analysis, Clinical trials, Double-Blind Method, Double-blind studies, Drug dosages, Drug Tolerance, Enzyme inhibitors, Female, Heterocyclic Compounds, 3-Ring - adverse effects, Heterocyclic Compounds, 3-Ring - therapeutic use, Humans, Inducible T-Cell Co-Stimulator Protein - antagonists & inhibitors, Infusions, Intravenous, Intention to Treat Analysis, Intravenous administration, Janus kinase, Janus Kinase Inhibitors - adverse effects, Janus Kinase Inhibitors - therapeutic use, Joint diseases, Kinases, Laboratories, Lymphocytes T, Male, Middle Aged, Patients, Remission, Remission (Medicine), Remission Induction, Rheumatoid arthritis, Rheumatology, Statistical analysis, Thromboembolism, Tumor necrosis factor-TNF